Phase 2Data readout

Detalimogene (EG-70)

Non-Muscle Invasive Bladder Cancer (NMIBC)

ENGNenGene

Expected catalystDecember 31, 2026Company guidance: Dec 31, 2026

Catalyst overview

Event details

Drug or asset: Detalimogene (EG-70)
Development stage: Phase 2
Event type: Data readout
Indication: Non-Muscle Invasive Bladder Cancer (NMIBC)

Research signalsHigh management interest

Research summary

What is being tracked?

This catalyst tracks a Phase 2 data readout for Detalimogene (EG-70) in Non-Muscle Invasive Bladder Cancer (NMIBC). The expected timing is based on the latest available company guidance and may change.

Development notes

06/15/26:- LEGEND data updated. Surfactant cohort enrolled. 12m data, FDA meeting, BLA filing H2 2026. 07/16/26:- Pre-BLA FDA meeting and BLA submission reiterated for H2 2026. Potential FDA approval targeted for 2027.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source